London-based biotech firm Sava, developer of real-time wearable biosensors, has raised $19 million in a Series A round, bringing its total funding to $32 million.
- Founded in 2019 by Renato Circi and Rafaël Michali, Sava Technologies develops a wearable biosensor platform powered by proprietary microsensing technology that detects multiple biomarkers just under the skin in real-time.
- The company’s first product, a pain-free, low-cost, and accurate Continuous Glucose Monitor (CGM), delivers molecular insights directly to a user’s smartphone, offering a scalable and accessible alternative to invasive, filament-based CGMs.
- In a world-first clinical trial, Sava’s biosensor demonstrated up to 10 days of accurate glucose monitoring, outperforming current microsensor technologies.
- The modular platform is capable of detecting additional molecules, paving the way for multi-analyte, personalised health monitoring that could transform chronic disease management and preventative care.
“Glucose is only the beginning. We have built a modular platform, capable of multi-molecule sensing. New molecules will create new use cases. What we’re building here is not just a device, but a whole new technological foundation for personalised healthcare, where anyone can use a biosensor to understand their health in real-time, at a molecular level," claims Renato Circi, co-founder and co-CEO of Sava.
Details of the deal
- Sava’s Series A round was led by Balderton Capital and Pentland Ventures, with participation from Norrsken VC, JamJar Investments, Italian Founders Fund, Athletico Ventures, SOLO Investments, and Exceptional Ventures.
“With its world-first technology, breakthrough clinical trial results, and new funding, Sava is positioned to lead the next wave of innovation in the $100B+ global health wearables market - beginning with CGM and creating a new market for real-time, multi-biomarker sensing. We are thrilled to be a part of the journey," explains Charlie Rubin, Investor at Pentland Ventures.
- Sava plans to use the Series A funding to expand its team, scale up automated manufacturing capabilities to meet target launch volumes, and accelerate clinical validation and regulatory approval of its next-generation wearable biosensor technology.
